logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Journal Article
|Research

Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial

Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, Borand L, Prak N, Kim CS, Lak KK, Hak C, Dim B, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX, CAMELIA (ANRS 1295-CIPRA KH001) Study Team
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Shortening the interval between antituberculosis treatment onset and initiation of antiretroviral therapy (ART) reduces mortality in severely immunocompromised human immunodeficiency virus (HIV)-infected patients with tuberculosis. A better understanding of causes and determinants of death may lead to new strategies to further enhance survival.

Countries

Cambodia

Subject Area

tuberculosisHIV/AIDS

Languages

English
DOI
10.1093/cid/ciu283
Published Date
01 Aug 2014
PubMed ID
24759827
Journal
Clinical Infectious Diseases
Volume | Issue | Pages
Volume 59, Issue 3
Issue Date
2014-04-23
Dimensions Badge
Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial | Journal Article / Research | MSF Science Portal